Literature DB >> 8915508

Comparative analysis of five highly conserved target sites within the HIV-1 RNA for their susceptibility to hammerhead ribozyme-mediated cleavage in vitro and in vivo.

A Ramezani1, S Joshi.   

Abstract

Moloney murine leukemia virus (MMLV)-derived pUCMoTiN-based retroviral vectors were engineered to allow constitutive and Tat (trans-activator of transcription)-inducible expression of five hammerhead ribozymes targeted against highly conserved sequences within the group antigen (Gag), protease (Pro), reverse transcriptase (RT), tat, and envelope (Env) coding regions of human immunodeficiency virus type-1 (HIV-1) RNA. Amphotropic retroviral vector particles were used to infect a human CD4+ lymphocyte-derived MT4 cell line. The pool of stable MT4 transductants expressing these ribozymes were each tested for their susceptibility to HIV-1 infection. RzTat conferred no protection to MT4 cells. RZGag and RzRT completely inhibited virus multiplication for 6 days. RzPro and RzEnv conferred the best protection, as they completely inhibited virus production for 12 and 15 days, respectively. No correlation was found between the degree of HIV-1 resistance conferred and the ability of these ribozymes to cleave their target RNA in vitro. From RzPro-expressing HIV-1-infected cells following virus escape, RzPro and target RNA sequences were amplified and checked for cleavage in vitro. The ribozyme expressed in these cells was shown to cleave the corresponding target RNA. Thus, a mutation in the ribozyme or target RNA does not seem to be the mechanism underlying virus escape.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8915508     DOI: 10.1089/oli.1.1996.6.229

Source DB:  PubMed          Journal:  Antisense Nucleic Acid Drug Dev        ISSN: 1087-2906


  4 in total

1.  Secondary structure prediction and in vitro accessibility of mRNA as tools in the selection of target sites for ribozymes.

Authors:  M Amarzguioui; G Brede; E Babaie; M Grotli; B Sproat; H Prydz
Journal:  Nucleic Acids Res       Date:  2000-11-01       Impact factor: 16.971

2.  Co-packaging of sense and antisense RNAs: a novel strategy for blocking HIV-1 replication.

Authors:  S F Ding; J Noronha; S Joshi
Journal:  Nucleic Acids Res       Date:  1998-07-01       Impact factor: 16.971

3.  Co-packaging of non-vector RNAs generates replication-defective retroviral vector particles: a novel approach for blocking retrovirus replication.

Authors:  S Joshi; S F Ding; S E Liem
Journal:  Nucleic Acids Res       Date:  1997-08-15       Impact factor: 16.971

4.  Control of HIV Infection In Vivo Using Gene Therapy with a Secreted Entry Inhibitor.

Authors:  Alexander Falkenhagen; Jastaranpreet Singh; Sabah Asad; Danila Leontyev; Stanley Read; Juan Carlos Zúñiga-Pflücker; Sadhna Joshi
Journal:  Mol Ther Nucleic Acids       Date:  2017-09-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.